Phaseline

Targets › VEGFB

VEGFB (Vascular endothelial growth factor B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology.

Growth factor for endothelial cells. VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis. (UniProt, P49765)

Open in Phaseline: the race on VEGFB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Eye Disease Prevention and Treatment CenterConbercept
Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor
VEGFA, VEGFB, PGF, VEGFCPhase 4Diabetic Macular Edema–

Conditions

Diabetic Macular Edema (1)

Modalities

antibody (1)

Companies

Shanghai Eye Disease Prevention and Treatment Center (1)

Related targets

VEGFA (1) PGF (1) VEGFC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.